Nurexone Biologic Inc Stock Price, News & Analysis

NurExone (OTCQB: NRXBF) announced on December 12, 2025 that it has begun evaluating Israeli partners for small-scale GMP-aligned manufacturing of its lead candidate ExoPTEN to support preparation for a potential First-in-Human use pathway, pending regulatory approval.

NurExone reported new analytical data showing its MSC-derived exosomes convert AMP to adenosine at a significantly higher per-particle rate versus a commercial control (t-test, p < 0.01). The company engaged Russo Partners for a short consulting project for US$6,600.

NurExone Biologic (OTCQB: NRXBF, TSXV: NRX) reported Q3 2025 results and a corporate update on Nov 28, 2025. Key highlights include C$3.2 million gross proceeds from accelerated warrant exercises, C$1.4 million raised in August/September 2025 private placements, and strengthened IP with a U.S. notice of allowance (Sept 8, 2025) and an Israel patent grant (Nov 11, 2025). Preclinical programs showed reproducible, dose-dependent vision recovery in glaucoma models and dose-dependent motor recovery in acute spinal cord injury. The company secured an incentive offer up to US$0.26 million for a planned Indianapolis GMP facility, granted 1,450,000 RSUs and 271,700 options, and reported a Q3 net loss of US$1.47 million.

NurExone (OTCQB: NRXBF) announced it received C$3,185,994.43 in gross proceeds from accelerated warrant exercises completed after acceleration notices issued on October 8, 2025.

The company reported C$1,207,418.88 from 2,515,456 September 2023 warrants at C$0.48 each and C$1,978,575.55 from 5,653,073 January 2024 warrants at C$0.35 each. Proceeds will be used for general corporate purposes and working capital to support development of its exosome-based therapeutic platform, including ExoPTEN. NurExone also received finalist recognition at Falling Walls (Berlin) and Prix Galien Bridges (Stockholm, December 5, 2025).

NurExone (OTCQB: NRXBF) was accepted into the ARMI BioFab Startup Lab under the federally supported BioFabUSA program on Nov 3, 2025. The program aims to accelerate translation of regenerative innovations into scalable, commercially viable manufacturing.

The company said participation could support plans by its U.S. subsidiary Exo-Top to develop a GMP-compliant facility for naive exosome production and may enhance its value proposition to strategic partners and shareholders.

NurExone (OTCQB: NRXBF) announced that Dr. Ina Sarel, Director of Clinical and Regulatory Affairs, will present at the Precision EV Forum 2025 in Cambridge, UK on October 27–28, 2025. Dr. Sarel will speak on October 28 about regulatory challenges in the clinical development of ExoPTEN: MSC EVs loaded with PTEN-siRNA and will join a panel on regulatory pathways for exosome therapeutics.

The invitation highlights international interest in NurExone’s lead program ExoPTEN, which has Orphan Drug Designation for acute spinal cord injury and has shown nerve-function restoration and reduced inflammation in preclinical models for spinal cord and optic nerve damage.

NurExone (OTCQB: NRXBF) reported preclinical data showing its lead candidate ExoPTEN produced a reproducible, dose-dependent recovery of visual function in an optic nerve crush (ONC) glaucoma model.

Higher ExoPTEN doses restored scotopic threshold response (STR) amplitudes to levels comparable to uninjured eyes. The study used low (4E+8 particles) and high (4E+9 particles) extrachoroidal doses given twice and measured STR by ERG; responses >5µV were considered detectable.

The company also accelerated expiry of September 2023 and January 2024 warrants, setting a new expiry of 5:00 p.m. (Calgary) on Nov 7, 2025, and noted potential gross proceeds of approximately C$3.2 million if all warrants are exercised. POSITIVE Communications agreement extended to July 10, 2026 with added monthly expense reimbursement.

NurExone Biologic (OTCQB: NRXBF) has announced plans to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana through its subsidiary Exo-Top Inc. The company has secured an incentive offer of up to $255,000 for this expansion.

The planned GMP-compliant facility will serve as Exo-Top's U.S. manufacturing base, producing exosomes for both NurExone's therapeutic pipeline and business-to-business opportunities in regenerative aesthetics. The expansion aligns with Indiana's robust life sciences sector, which generates over $99 billion in annual economic output and has attracted more than $1.5 billion in venture investments since 2019.

This strategic move supports NurExone's progress toward first-in-human clinical trials of ExoPTEN and its plans to uplist to a major U.S. stock exchange.

NurExone Biologic (OTCQB: NRXBF), a biopharmaceutical company focused on exosome-based regenerative therapies, announced several corporate updates. The company received a patent grant in Israel for "Production of Extracellular Vesicles from Stem Cells", complementing their recent U.S. patent allowance.

The company completed a non-brokered private placement raising C$632,655.68 through the issuance of 930,376 units at C$0.68 per unit. Each unit includes one common share and a half warrant exercisable at C$0.88 for 36 months. The proceeds will support preclinical pipeline and U.S. manufacturing initiatives.

Additionally, NurExone announced upcoming presentations at two major U.S. conferences: the 7th Annual Exosome-Based Therapeutic Development Summit and the Bioprocess International Conference in Boston, where company executives will showcase their ExoTherapy technology.

NurExone Biologic (OTCQB: NRXBF) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its proprietary exosome manufacturing process. The patent covers the company's 3D scaffold and shear-stress based bioreactor system for producing stem cell-derived exosomes.

This milestone, combined with the company's GMP-grade Master Cell Bank acquisition in December 2024, strengthens NurExone's supply chain readiness. The technology, developed at the Technion, enables scalable and reproducible exosome production for regenerative therapies. The patent is part of a broader international patent family and is exclusively licensed worldwide to NurExone from the Technion Research and Development Foundation.